glp 1 studies Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature Glucagon-like peptide-1 receptor: mechanisms and

Moreover, promising outcomes from various large-scale cardiovascular outcome trials (CVOTs) have indicated that GLP-1RAs could mitigate the risk of major adverse cardiovascular events (MACE) in T2DM patients with an elevated cardiovascular risk profile (Marso et al., 2016a

This approach differs from both traditional immunosuppression and even newer biologics

9 : 6771 Peng H, Poo M

The excitement comes from its potential to help with slow-to-heal injuries like tendinopathies, ligament strains, muscle tears, or even chronic pain recovery

In addition, there is a likely analogy (see for review i.e., (Seiwerth et al., 2018)) with the attenuated fibrosis and scar formation in other tissues (i.e., the skin, muscle, tendon, and ligament) (Mikus et al., 2001

Furthermore, the results of some secondary analyses should be interpreted with caution due to wide confidence intervals stemming from the rarity of the outcomes